Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study
Islam M Miligy,
Rachna Awasthi,
Yasmeen Mir
et al.
Abstract:AimsStandard neoadjuvant endocrine therapy (NAET) is used for 6–9 months to downstage hormone‐receptor‐positive breast cancer. Bridging ET was introduced during the COVID‐19 pandemic to delay surgical intervention. There are no data in the literature on the effect of short course therapy on tumour response. We aimed to analyse the effect of bridging ET and validate the previously proposed neoadjuvant ET pathological reporting criteria.Methods and ResultsThis was a multicentre cohort of 256 patients who receive… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.